Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Photocure ASA (PHCUF)
OTHER OTC:PHCUF
Holding PHCUF?
Track your performance easily
PHCUF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.00 - $7.34
Previous Close$4.94
Volume36.40K
Average Volume (3M)615.00
Market Cap
$133.01M
Enterprise Value$112.61M
Total Cash (Recent Filing)kr264.65M
Total Debt (Recent Filing)kr39.54M
Price to Earnings (P/E)122.6
Beta0.64
Next Earnings
Feb 26, 2025EPS Estimate
<$0.01Last Dividend Ex-Date
May 23, 2013Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. Volume615
Standard Deviation0.15
R-Squared0.00533
Alpha0.00179
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)3.58
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Photocure ASA News
PremiumCompany Announcements
Photocure ASA Reports Strong Q3 2024 Growth
PremiumCompany Announcements
Photocure ASA Sees Strong Q3 Revenue Growth
PremiumCompany Announcements
Photocure ASA to Announce Q3 Financial Results
PremiumCompany Announcements
Photocure’s Hexvix Gains Approval in ChinaPremiumCompany Announcements
Promising Trial Results for Cervical Lesion TreatmentPremiumCompany Announcements
Photocure Expands Bladder Cancer Treatment in South Africa
PremiumCompany Announcements
Photocure Announces Cevira’s Successful Phase III ResultsOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.05% Mutual Funds
― Other Institutional Investors
99.79% Public Companies and
Individual Investors
PHCUF FAQ
What was Photocure ASA’s price range in the past 12 months?
Photocure ASA lowest stock price was $4.00 and its highest was $7.34 in the past 12 months.
What is Photocure ASA’s market cap?
Currently, no data Available
When is Photocure ASA’s upcoming earnings report date?
Photocure ASA’s upcoming earnings report date is Feb 26, 2025 which is in 102 days.
How were Photocure ASA’s earnings last quarter?
Photocure ASA released its earnings results on Nov 13, 2024. The company reported -$0.012 earnings per share for the quarter, beating the consensus estimate of -$0.022 by $0.01.
Is Photocure ASA overvalued?
According to Wall Street analysts Photocure ASA’s price is currently Overvalued.
Does Photocure ASA pay dividends?
Photocure ASA pays a Notavailable dividend of $0.18 which represents an annual dividend yield of N/A. See more information on Photocure ASA dividends here
What is Photocure ASA’s EPS estimate?
Photocure ASA’s EPS estimate is <$0.01.
How many shares outstanding does Photocure ASA have?
Photocure ASA has 27,120,820 shares outstanding.
What happened to Photocure ASA’s price movement after its last earnings report?
Photocure ASA reported an EPS of -$0.012 in its last earnings report, beating expectations of -$0.022. Following the earnings report the stock price went up 1.089%.
Which hedge fund is a major shareholder of Photocure ASA?
Currently, no hedge funds are holding shares in PHCUF
---
Photocure ASA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.88%
12-Months-Change
Fundamentals
Return on Equity
2.41%
Trailing 12-Months
Asset Growth
1.62%
Trailing 12-Months
Company Description
Photocure ASA
PhotoCure ASA is a Norway based specialty pharmaceutical company. Its technology platform is focused on the field of photodynamic diagnosis and treatment in the areas of dermatology and cancer. The group has operations in Norway, Sweden, Denmark, Finland and the United States. The operating segments of the group are Commercial franchise and Development portfolio. The company markets product through its commercial operation in the Nordic region under the brand name Hexvix and in the US under the brand name Cysview. It generates prime revenue from the Commercial franchise segment which includes the Hexvix and Cysview products. In addition, the firm also has two device products, Cevira and Visonac, both targeted at indications with medical need and market potential.
---
PHCUF Company Deck
---
PHCUF Earnings Call
Q3 2024
0:00 / 0:00
---
Technical Analysis
---